한글목차

비바이러스성 약물 전달 시스템 시장 규모는 최근 급성장하고 있습니다. 2025년 98억 4,000만 달러에서 2026년에는 112억 6,000만 달러에 이르고, CAGR 14.4%의 성장이 전망되고 있습니다. 지금까지의 성장 요인으로는 바이러스성 전달 방식에 대한 의존도, 비바이러스성 기술에 대한 낮은 인지도, 신흥 바이오 의약품 개발, 약물 전달에 대한 초기 규제 프레임워크, 나노 입자에 대한 초기 단계의 학술적 연구 집중 등을 들 수 있습니다.

비바이러스성 약물 전달 시스템 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 190억 7,000만 달러에 이르고, CAGR은 14.1%를 나타낼 전망입니다. 예측 기간 동안의 성장은 고분자 기반 캐리어 기술의 발전, RNA 및 DNA 치료제의 성장, 맞춤의료에 대한 투자 증가, 위탁개발생산기관(CDMO)의 확대, 제약기업과 학술기관 간의 협력 강화에 기인할 것으로 보입니다. 예측 기간 동안 주요 동향으로는 표적 치료를 위한 비바이러스성 전달 플랫폼의 채택 확대, 나노입자 및 리포좀 기반 캐리어의 사용 증가, 면역 반응 감소 및 안전성 향상에 대한 집중, 개인 맞춤형 의료 및 표적 치료제의 성장, CDMO의 확대, 학술 연구와의 협력 강화 등이 있습니다. 등을 꼽을 수 있습니다.

개인 맞춤형 의료에 대한 수요 증가는 향후 몇 년 동안 비바이러스성 약물 전달 시스템 시장의 성장을 견인할 것으로 예측됩니다. 맞춤형 의료는 개인의 유전자 프로파일, 생활습관, 환경적 요인에 따라 맞춤형 치료를 하는 의료 접근법입니다. 맞춤형 의료는 환자별로 질병의 근본 원인을 파악하여 보다 효과적인 치료가 가능하기 때문에 그 수요가 증가하고 있습니다. 비바이러스성 약물전달시스템은 약물이나 유전물질을 표적 세포에 안전하고 정확하게 전달하여 위험을 최소화하고 치료의 정확도를 향상시켜 맞춤형 의료를 지원하는 역할을 합니다. 예를 들어, 미국 비영리단체 '맞춤의료연합'에 따르면, 2024년 2월 기준 미국 식품의약국(FDA)은 2023년 희귀질환 환자를 위한 16개의 새로운 맞춤 치료법을 승인했습니다. 이는 2022년 6건에서 증가한 수치입니다. 따라서 개인 맞춤형 의료에 대한 수요 증가가 비바이러스성 약물 전달 시스템 시장의 성장을 가속하고 있습니다.

비바이러스성 약물 전달 시스템 시장에서 활동하는 주요 기업들은 RNA 기반 치료제의 개발 및 전달을 간소화하기 위해 사전 최적화 이온화 지질 혼합 시스템과 같은 첨단 기술에 집중하고 있습니다. 사전 최적화 이온화 지질 혼합 시스템은 RNA 분자를 지질 나노입자 내에 효율적으로 봉입하여 유전자 치료 응용 분야에서 안정성 향상, 페이로드 보호 및 표적 전달을 보장하도록 설계된 제형 기술입니다. 예를 들어, 2024년 9월 미국 생명공학 기업 Cytiva는 자사의 NanoAssemblr Ignite 및 Ignite+ 플랫폼과 호환되는 RNA 전달용 지질 나노입자(LNP) 키트를 발표했습니다. 이 시스템은 특히 감염성 백신 개발에서 RNA 페이로드의 신속한 스크리닝과 효과적인 전달 검증을 가능하게 하는 즉시 사용 가능한 이온화 지질 혼합물을 특징으로 합니다. 자동화된 마이크로유체 플랫폼과 원활하게 통합되어 GMP 등급 부품을 사용한 확장 가능한 제조를 지원하며, 프로토콜과 개념증명 데이터를 제공하여 초기 발견 단계부터 임상 평가까지 사용자를 지원합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Non-viral drug delivery systems refer to approaches for administering therapeutic agents into the body without the use of viral vectors. These systems employ physical, chemical, or mechanical methods such as nanoparticles, liposomes, and polymer-based carriers to safely transport drugs to specific target sites. They are designed to minimize the risks associated with viral delivery, including immune responses and insertional mutagenesis. This strategy improves treatment effectiveness and enhances patient safety across a wide range of medical conditions.

The main types of molecules delivered through non-viral drug delivery systems include biologics and small molecules. Biologics are therapeutics derived from living sources and include proteins, peptides, monoclonal antibodies, and nucleic acid-based therapies such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). The biologic types delivered comprise RNA, DNA, proteins or peptides, and antibodies. The key end users include pharmaceutical and biotechnology companies, academic and research institutions, contract development and manufacturing organizations (CDMOs), as well as hospitals and clinics.

Tariffs have affected the non-viral drug delivery systems market by increasing the cost of imported materials such as specialized polymers, lipids, and nanoparticles. Segments including RNA-based therapeutics and liposome carriers are most impacted, particularly in regions like Asia-Pacific where manufacturing hubs such as China and India face import duties. This has led to higher production costs and adjustments in supply chains. Positively, tariffs are driving local production, innovation in alternative materials, and greater investment in domestic manufacturing capabilities.

The non-viral drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides non-viral drug delivery systems market statistics, including non-viral drug delivery systems industry global market size, regional shares, competitors with a non-viral drug delivery systems market share, detailed non-viral drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral drug delivery systems industry. This non-viral drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-viral drug delivery systems market size has grown rapidly in recent years. It will grow from $9.84 billion in 2025 to $11.26 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to reliance on viral delivery methods, limited awareness of non-viral techniques, emerging biologics development, initial regulatory frameworks for drug delivery, early academic research focus on nanoparticles.

The non-viral drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $19.07 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to advancements in polymer-based carriers, growth of rna and dna therapeutics, increasing investment in personalized medicine, expansion of contract development and manufacturing organizations (cdmos), rising collaborations between pharma and academic institutions. Major trends in the forecast period include rising adoption of non-viral delivery platforms for targeted therapies, increasing use of nanoparticles and liposome-based carriers, focus on reducing immune response and enhancing safety, growth in personalized medicine and targeted therapeutics, expansion of cdmos and academic research collaborations.

The rising demand for personalized medicines is anticipated to drive the growth of the non-viral drug delivery systems market in the coming years. Personalized medicine is a healthcare approach that customizes treatment based on an individual's genetic profile, lifestyle, and environmental factors. The demand for personalized medicine is increasing because it enables more effective therapies by addressing the specific underlying causes of disease in each patient. Non-viral drug delivery systems support personalized medicine by enabling the safe and precise delivery of drugs or genetic material to target cells, minimizing risks and improving treatment accuracy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases, up from 6 approvals in 2022. Therefore, the growing demand for personalized medicines is fueling the growth of the non-viral drug delivery systems market.

Major companies operating in the non-viral drug delivery systems market are concentrating on advanced technologies, such as pre-optimized ionizable lipid mix systems, to simplify the development and delivery of RNA-based therapeutics. A pre-optimized ionizable lipid mix system is a formulation technology designed to efficiently encapsulate RNA molecules within lipid nanoparticles, ensuring enhanced stability, protection of the payload, and targeted delivery for gene-based therapeutic applications. For example, in September 2024, Cytiva, a US-based biotechnology company, introduced an RNA delivery lipid nanoparticle (LNP) kit compatible with its NanoAssemblr Ignite and Ignite+ platforms. This system features a ready-to-use ionizable lipid mix that enables rapid screening of RNA payloads and effective delivery validation, particularly for infectious disease vaccine development. It integrates seamlessly with automated microfluidic platforms, supports scalable manufacturing using GMP-grade components, and provides protocols along with proof-of-concept data to support users from early discovery through clinical evaluation.

In September 2023, SOHM Inc., a US-based pharmaceutical company, acquired ABBIE from CGA 369 for $10 million. Through this acquisition, SOHM enhanced its capabilities in delivering large genetic payloads using integrase-based, non-viral technologies. ABBIE is being developed as an off-the-shelf gene-editing kit, with commercialization planned for 2024 and human trials expected by late 2025. CGA 369 is a US-based biotechnology company specializing in non-viral, integrase-based gene-editing and genetic payload delivery systems.

Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.

North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-viral drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral drug delivery systems market consists of sales of exosomes, cell-penetrating peptides, and nanocrystals. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Drug Delivery Systems Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses non-viral drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral drug delivery systems market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type Of Molecule Delivered: Biologics; Small Molecules
• 2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA); Deoxyribonucleic Acid (DNA); Proteins or Peptides; Antibodies
• 3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Development And Manufacturing Organizations (CDMOs); Hospitals And Clinics
• Subsegments:
• 1) By Biologics: Peptides; Proteins; Monoclonal Antibodies; RNA-based Therapeutics; DNA-based Therapies
• 2) By Small Molecules: Chemotherapeutics; Anti-inflammatories; Antivirals; Antibiotics; Hormonal Drugs
• Companies Mentioned: Evonik Industries AG; Cytiva; Arcturus Therapeutics Holdings Inc.; CureVac N.V.; PolyPid Ltd; Ethris GmbH; Entos Pharmaceuticals Inc.; Liquidia Technologies Inc.; ReCode Therapeutics Inc.; Enable Injections Inc.; GenEdit Inc.; N4 Pharma Plc; Hopewell Therapeutics Inc.; Tiba Biotech LLC; Vesigen Therapeutics Inc.; Carmine Therapeutics Inc.; Evox Therapeutics Ltd; InnoCore Pharmaceuticals BV; Nanomerics Ltd; DelSiTech Ltd; Curapath Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Non-Viral Drug Delivery Systems Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Non-Viral Drug Delivery Systems Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Non-Viral Drug Delivery Systems Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Non-Viral Drug Delivery Systems Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Industry 4.0 & Intelligent Manufacturing
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Non-Viral Delivery Platforms For Targeted Therapies
  • 4.2.2 Increasing Use Of Nanoparticles And Liposome-Based Carriers
  • 4.2.3 Focus On Reducing Immune Response And Enhancing Safety
  • 4.2.4 Growth In Personalized Medicine And Targeted Therapeutics
  • 4.2.5 Expansion Of Cdmos And Academic Research Collaborations

5. Non-Viral Drug Delivery Systems Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biotechnology Companies
• 5.3 Academic And Research Institutes
• 5.4 Contract Development And Manufacturing Organizations (Cdmos)
• 5.5 Hospitals And Clinics

6. Non-Viral Drug Delivery Systems Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Non-Viral Drug Delivery Systems Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Non-Viral Drug Delivery Systems PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Non-Viral Drug Delivery Systems Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Non-Viral Drug Delivery Systems Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Non-Viral Drug Delivery Systems Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Non-Viral Drug Delivery Systems Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Non-Viral Drug Delivery Systems Market Segmentation

• 9.1. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Biologics, Small Molecules
• 9.2. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
• 9.3. Global Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
• 9.4. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
• 9.5. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs

10. Non-Viral Drug Delivery Systems Market Regional And Country Analysis

• 10.1. Global Non-Viral Drug Delivery Systems Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Non-Viral Drug Delivery Systems Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Non-Viral Drug Delivery Systems Market

• 11.1. Asia-Pacific Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Non-Viral Drug Delivery Systems Market

• 12.1. China Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Non-Viral Drug Delivery Systems Market

• 13.1. India Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Non-Viral Drug Delivery Systems Market

• 14.1. Japan Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Non-Viral Drug Delivery Systems Market

• 15.1. Australia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Non-Viral Drug Delivery Systems Market

• 16.1. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Non-Viral Drug Delivery Systems Market

• 17.1. South Korea Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Non-Viral Drug Delivery Systems Market

• 18.1. Taiwan Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Non-Viral Drug Delivery Systems Market

• 19.1. South East Asia Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Non-Viral Drug Delivery Systems Market

• 20.1. Western Europe Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Non-Viral Drug Delivery Systems Market

• 21.1. UK Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Non-Viral Drug Delivery Systems Market

• 22.1. Germany Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Non-Viral Drug Delivery Systems Market

• 23.1. France Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Non-Viral Drug Delivery Systems Market

• 24.1. Italy Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Non-Viral Drug Delivery Systems Market

• 25.1. Spain Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Non-Viral Drug Delivery Systems Market

• 26.1. Eastern Europe Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Non-Viral Drug Delivery Systems Market

• 27.1. Russia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Non-Viral Drug Delivery Systems Market

• 28.1. North America Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Non-Viral Drug Delivery Systems Market

• 29.1. USA Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Non-Viral Drug Delivery Systems Market

• 30.1. Canada Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Non-Viral Drug Delivery Systems Market

• 31.1. South America Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Non-Viral Drug Delivery Systems Market

• 32.1. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Non-Viral Drug Delivery Systems Market

• 33.1. Middle East Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Non-Viral Drug Delivery Systems Market

• 34.1. Africa Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Non-Viral Drug Delivery Systems Market Regulatory and Investment Landscape

36. Non-Viral Drug Delivery Systems Market Competitive Landscape And Company Profiles

• 36.1. Non-Viral Drug Delivery Systems Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Non-Viral Drug Delivery Systems Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Non-Viral Drug Delivery Systems Market Company Profiles
  • 36.3.1. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Cytiva Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Arcturus Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. CureVac N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. PolyPid Ltd Overview, Products and Services, Strategy and Financial Analysis

37. Non-Viral Drug Delivery Systems Market Other Major And Innovative Companies

• Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd

38. Global Non-Viral Drug Delivery Systems Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Non-Viral Drug Delivery Systems Market

40. Non-Viral Drug Delivery Systems Market High Potential Countries, Segments and Strategies

• 40.1 Non-Viral Drug Delivery Systems Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Non-Viral Drug Delivery Systems Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Non-Viral Drug Delivery Systems Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer